(MedPage Today) — DENVER — A majority of patients with non-locally treated brain metastases from kidney cancer remained free of metastatic progression for at least 6 months when treated with cabozantinib (Cabometyx), a small prospective study…
Source link : https://www.medpagetoday.com/meetingcoverage/ikcs/118548
Author :
Publish date : 2025-11-15 22:44:00
Copyright for syndicated content belongs to the linked Source.
